Biosimilars are a
prescription for
better health.

In the U.S., Biosimilars could lead to over $130 billion is savings by 2025, and have been used in over 364 million days of patient therapy.

Click here to view the Biosimilars Patient Resource Center

Visit our Biosimilars Patient Resource Center!

Whether you are a patient, caregiver, or you just want to learn more about biosimilars, our Biosimilars Patient Resource Center tells you everything you need to know about biosimilars so you can make more informed decisions.  Learn More.


2022 U.S. Generic and Biosimilar Savings Report

Our annual savings report, featuring data from IQVIA, found that biosimilars generated $7 billion in savings last year. Read the report to see how else biosimilars are delivering on their promise. Learn more.


The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines.

Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market


Biosimilars approved in the U.S.


Billion in potential savings for patients and payers


Million days of patient therapy where biosimilars were used


Million additional days of patient therapy

The Benefits of Biosimilars

Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.

This increases access to needed medications for patients, strengthens our economy and benefits our society.

View resources for:

Recent Blogs & Resources

What Patients Are Saying

Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
Helen, 41, Winter Springs, Florida treated her non-Hodgkin lymphoma with a biosimilar

“Because I have an incurable form of non-Hodgkin lymphoma, I know my medication journey will continue. It is nice to know that when I need a biosimilar again, it will be there for me.”

Helen, 41, Florida

Listen to their stories.

You Can Make A Difference

As the role of biosimilar medicines in our health care system continues to grow, it is essential that patients advocate for affordable biosimilars with their lawmakers. Subscribe to the Biosimilars Bulletin and for alerts on policies that affect your access to these life-saving medicines.

Recent Tweets